San Francisco, CA, United States of America

Nicole Galloway

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Portland, OR (US) (2016)
  • San Francisco, CA (US) (2018)

Company Filing History:


Years Active: 2016-2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nicole Galloway: Innovator in HIV-1 Treatment

Introduction

Nicole Galloway is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of medical research, particularly in the treatment of HIV-1 infection and AIDS. With a total of 2 patents, her work is paving the way for innovative therapies that address critical health challenges.

Latest Patents

Nicole Galloway's latest patents focus on the treatment of HIV-1 infection and AIDS. These patents provide compositions and methods for treating patients with HIV-1 infection and/or AIDS using small molecule compounds. Specifically, her inventions include inhibitors for the activation and/or activity of caspase-1. These inhibitors not only prevent the cell death of CD4 T-cells in populations comprising both HIV-1 infected and uninfected CD4 T-cells but also inhibit inflammation and pyroptosis.

Career Highlights

Nicole Galloway is affiliated with the J. David Gladstone Institutes, where she conducts her research. Her work has garnered attention for its potential to improve the lives of those affected by HIV-1 and AIDS.

Collaborations

Nicole collaborates with esteemed colleagues such as Warner C Greene and Gilad Doitsh, further enhancing the impact of her research through teamwork and shared expertise.

Conclusion

Nicole Galloway is a trailblazer in the field of HIV-1 treatment, with her innovative patents contributing to significant advancements in medical science. Her dedication to improving patient outcomes is commendable and highlights the importance of research in combating infectious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…